COMPARED WITH PATIENTS WITHOUT SHPT

Welcome to SHPT Challenges

This website contains information about secondary hyperparathyroidism (SHPT). It is intended to provide information to an international audience outside of the USA.

I confirm that I am a healthcare professional practising outside of the USA.

I confirm that I have read and understood the website’s Privacy policy, Cookie settings and Terms of use.

I am a member of the public

You are now leaving our website and heading to a third-party website that we do not operate. We are not responsible for the content of the third-party website. You are advised to review its privacy policy as it may differ from ours.

Are you sure you want to leave?

Confirm

Cancel

SHPT is associated
with increased
morbidity, mortality
and disease
progression
in patients with
ND-CKD⁷

/sites/g/files/brlbcj1106/files/2020-04/bricks-min-min.png

COMPARED WITH PATIENTS WITHOUT SHPT,
PATIENTS WITH SHPT ARE >5X MORE LIKELY
TO BE INITIATED ON DIALYSIS OR DIE⁷

/sites/g/files/brlbcj1106/files/2020-06/Kaplan%E2%80%93Meier_analysis_Graph-min.png

CKD: chronic kidney disease; ND-CKD: non-dialysis chronic kidney disease; SHPT: secondary hyperparathyroidism.

ABOUT SHPT

Welcome to SHPT Challenges

SHPT is associated with increased morbidity, mortality and disease progression in patients with ND-CKD7

COMPARED WITH PATIENTS WITHOUT SHPT, PATIENTS WITH SHPT ARE >5X MORE LIKELY TO BE INITIATED ON DIALYSIS OR DIE7

SHPT is associated
with increased
morbidity, mortality
and disease
progression
in patients with
ND-CKD⁷

COMPARED WITH PATIENTS WITHOUT SHPT,
PATIENTS WITH SHPT ARE >5X MORE LIKELY
TO BE INITIATED ON DIALYSIS OR DIE⁷